Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX - Free Report) soared on Friday, and were up over 90% at one point in afternoon trading. PTGX closed the day up 83.7% to $14.20 a share.
In its Q1 earnings report, PTGX provided an update to its clinical development programs. The company said it chose polycythemia vera, a kind of blood cancer where bone marrow produces too many red blood cells as the first indication for its lead candidate PTG-300.
PTG-300 is a treatment that imitates a natural peptide hormone called hepcidin, which regulates iron absorption and utilization in the body. It also plays a key role in red blood cell development.
CEO Dinesh V. Patel said the company is focused on “rapidly advancing” PTG-300 and deferring the start of an ulcerative colitis candidate’s Phase 2 study. This will help reduce expenses and extend its cash pile another 6 months through mid-2022.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>